Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease

New England Journal of Medicine

Volumn 336, Issue 5, 1997, Pages 332-336

  Johannesson, Magnus ^a   Jönsson, Bengt ^a   Kjekshus, John ^b   Olsson, Anders G ^c   Pedersen, Terje R ^d   Wedel, Hans ^e  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

^c LINKÖPING UNIVERSITY   (Sweden)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PLACEBO; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HOSPITAL COST; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SWEDEN;

ADULT; AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MARKOV CHAINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; SIMVASTATIN; VALUE OF LIFE;

EID: 1842404801     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199701303360503     Document Type: Article

References (24)

1. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990;81:1721-33.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Idem. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-5.
4. Pedersen TR, Kjekshus I, Berg K, et al. Cholesterol lowering and the use of health care resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996;93:1796-802.
5. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-7.
6. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment - a review of methodological issues. Health Policy 1991;19:55-78.
7. Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 1990;6:93-103.
8. Russell L. Is prevention better than cure? Washington, D.C.: Brookings Institution, 1986.
9. Weinstein MC, Stason WB. Foundations of cost effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
10. Johannesson M, Hedbrant J, Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inf (Lond) 1991;16:355-62.
11. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987:131-5. (IARC scientific publications no. 32.)
12. FASS 1995: Läkemedel i Sverige. Stockholm, Sweden: Läkemedelsin-formation AB, 1995.
13. DRG vid Kungälvs sjukhus. Spri rapport 395. Stockholm, Sweden: Spri, 1995.
14. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24. [Erratum, N Engl J Med 1995;333:267.]
15. Statistisk årsbok '96 (statistical yearbook of Sweden). Stockholm, Sweden: Statistiska Centralbyrån, 1995.
16. Gerdtham U-G. The impact of aging on health care expenditure in Sweden. Health Policy 1993;24:1-8.
17. Johannesson M, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med 1996;240:23-9.
18. Johannesson M, Borgquist L, Nilsson-Ehle P, Jönsson B, Ekbom T, Lindholm LH. The cost of screening for hypercholesterolaemia - results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest 1993;53:725-32.
19. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993;13:161-5.
20. Discounting health care: only a matter of timing? Lancet 1992;340: 148-9.
21. Tosteson AN, Rosenthal DI, Melton LJ III, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594-603.
22. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med 1990;112:192-202.
23. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol 1991;67:789-96.
24. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease: JAMA 1991;265:1145-51.